The recent failure of Pfizer's late-stage trial for Duchenne muscular dystrophy (DMD) gene therapy marks a significant setback for patients but opens the door for competitors like Sarepta Therapeutics. Pfizer’s…
Breaking News! Pfizer Inc. has just received FDA approval for Beqvez™, a groundbreaking gene therapy for adults with moderate to severe hemophilia B. Beqvez offers a life-changing treatment option for…
UPDATE: A New FDA approval has been released for Breyanzi. A request was submitted for approval for the expanded indication to include Relapsed and Refractory (R/R) Follicular Lymphoma and Marginal Zone…
Another new FDA approval expanding the indication for Abecma. Previously, it was approved only after failure of 4 or more prior lines of therapy. However, due to showing a progression-free…
Orchard's recent reveal of Lenmeldy's $4.25 million price tag has sparked conversations about the affordability of groundbreaking gene therapies. While Lenmeldy stands as the most expensive one-time gene therapy, it's…
Exciting advancements are on the horizon for Gene & Cell Therapies, particularly in the realm of treating hematologic and rare diseases. The anticipation surrounding the FDA approvals expected in 2024…
Renalogic saved us significant money on a dialysis claim. It (the initial dialysis claim) came in close to a million dollars, and they immediately reduced it by 80%.
Client
Renalogic and its cost containment methodology decreased that first dialysis claim to $120,000, and it didn’t even hit their Stop-Loss policy. It was a home run for everybody.
Broker-Partner
It is so nice to have someone fighting for me and helping me through all of this.
29 y/o Survivor Diagnosed with Ovarian Cancer
Struggles turn us into people we didn’t know we could be, and cancer is no different. CancerCARE saved my life when I was misdiagnosed with lymphoma weeks after my cervical cancer diagnosis. They helped me turn my struggle into grace, strength, and knowledge to fight back. And that is an empowering combination.
29 y/o Survivor Mis-diagnosed with Lymphoma
Your ability to identify and stop people from progressing to ESRD is amazing. You’ve saved us millions of dollars and helped numerous employees in their healthcare journey. We are so grateful to have a vendor like Renalogic.
Client
We have been working with Interlink for over fifteen years utilizing their Transplant COE. We greatly value their staff expertise, support, and flexibility. Several of our self-funded clients are in a market that had historically directed transplants to facilities that were close geographically, but prohibitively expensive. Interlink was able to provide concise and specific outcomes and cost data to illustrate that an alternative facility in a location just a little further away made much more sense. Without the outcomes data, we could not have convinced members and providers to re-evaluate and re-direct to more cost effective facilities which provide transplant patients with documented better outcomes. Interlink has been a strategic partner to us and our clients in this critical area of health plan management.
Senior Vice President, Lockton Companies
Symphony Benefits Solution delivers comprehensive healthcare benefit platforms, specializing in transplant, cancer, ESRD, and gene & cell therapy, ensuring exceptional patient outcomes through cutting-edge care and expertise.